|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
1,250,000,000 |
Market
Cap: |
81.33(B) |
Last
Volume: |
9,792,067 |
Avg
Vol: |
8,697,344 |
52
Week Range: |
$63.43 - $87.29 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 259 |
Guru Rank Value : 4.6 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
2,000 |
25,472 |
36,973 |
80,792 |
Total Sell Value |
$145,920 |
$2,022,270 |
$2,937,849 |
$6,445,296 |
Total People Sold |
1 |
3 |
3 |
4 |
Total Sell Transactions |
1 |
5 |
8 |
14 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Oday Daniel Patrick |
Chairman & CEO |
|
2022-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,003 |
260,396 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2022-03-01 |
4 |
D |
$60.26 |
$1,400,744 |
D/D |
(23,245) |
236,393 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2022-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
54,284 |
259,638 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-02-15 |
4 |
A |
$52.13 |
$18,141 |
D/D |
348 |
32,924 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2022-02-15 |
4 |
A |
$52.13 |
$18,141 |
D/D |
348 |
41,613 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2022-02-15 |
4 |
A |
$52.13 |
$18,141 |
D/D |
348 |
64,353 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-02-09 |
4 |
AS |
$63.89 |
$108,038 |
D/D |
(1,691) |
32,576 |
|
-5% |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2022-02-06 |
4 |
D |
$63.90 |
$33,228 |
D/D |
(520) |
24,219 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,864 |
24,739 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-02-06 |
4 |
D |
$63.90 |
$66,200 |
D/D |
(1,036) |
34,267 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,727 |
35,303 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2022-02-06 |
4 |
D |
$63.90 |
$49,011 |
D/D |
(767) |
59,706 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2022-02-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,817 |
60,473 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-02-01 |
4 |
AS |
$68.54 |
$963,682 |
D/D |
(14,061) |
32,576 |
|
-11% |
|
Mercier Johanna |
Chief Commercial Officer |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
18,630 |
30,778 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-01-26 |
4 |
D |
$67.34 |
$382,559 |
D/D |
(5,681) |
46,637 |
|
- |
|
Pletcher Brett A |
EVP,Corp Affairs & Gen Counsel |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
35,004 |
52,318 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2022-01-26 |
4 |
D |
$67.34 |
$2,278,314 |
D/D |
(33,833) |
205,354 |
|
- |
|
Oday Daniel Patrick |
Chairman & CEO |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
146,678 |
239,187 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2022-01-26 |
4 |
D |
$67.34 |
$243,501 |
D/D |
(3,616) |
58,656 |
|
- |
|
Dickinson Andrew D |
Chief Financial Officer |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
32,176 |
62,272 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2022-01-26 |
4 |
D |
$67.34 |
$26,532 |
D/D |
(394) |
22,875 |
|
- |
|
Wilfong Diane E |
SVP, Controller & CAO |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,871 |
23,269 |
|
- |
|
Parsey Merdad |
Chief Medical Officer |
|
2022-01-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,298 |
37,158 |
|
- |
|
Bluestone Jeffrey |
Director |
|
2021-12-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,041 |
1,041 |
|
- |
|
2511 Records found
|
|
Page 9 of 101 |
|
|